Phenolic compounds as histone deacetylase inhibitors: binding propensity and interaction insights from molecular docking and dynamics simulations
- PMID: 36781452
- DOI: 10.1007/s00726-023-03249-6
Phenolic compounds as histone deacetylase inhibitors: binding propensity and interaction insights from molecular docking and dynamics simulations
Abstract
Histone deacetylases are well-established target enzymes involved in the pathology of different diseases including cancer and neurodegenerative disorders. The approved HDAC inhibitor drugs are associated with cellular toxicities. Different phenolic compounds have been shown to possess inhibitory activities against HDACs and are, therefore, considered safer alternatives to synthetic compounds. Here, we elucidated the binding mode and calculated the binding propensity of some of the top phenolic compounds against different isoforms representing different classes of Zn2+ ion-containing HDACs using the molecular docking approach. Our data reaffirmed the activity of the studied phenolic compounds against HDACs. Binding interaction analysis suggested that these compounds can block the activity of HDACs with or without binding to the active site zinc metal ion. Furthermore, molecular dynamics (MD) simulations were carried out on the selected crystal and docking complexes of each selected HDAC isoform. Analysis of root-mean-square displacement (RMSD) showed that the phenolic compounds demonstrated a stable binding mode over 50 ns in a way that is comparable to the cocrystal ligands. Together, these findings can aid future efforts in the search for natural inhibitors of HDACs.
Keywords: HDACs; Molecular docking; Phenolic compounds; Zn2+ ion binding.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
References
-
- Alseksek RK, Ramadan WS, Saleh E, El-Awady R (2022) The role of HDACs in the response of cancer cells to cellular stress and the potential for therapeutic intervention. Int J Mol Sci. https://doi.org/10.3390/ijms23158141 - DOI - PubMed - PMC
-
- Berger A, Venturelli S, Kallnischkies M, Böcker A, Busch C, Weiland T, Noor S, Leischner C, Weiss TS, Lauer UM, Bischoff SC, Bitzer M (2013) Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J Nutr Biochem 24(6):977–985. https://doi.org/10.1016/j.jnutbio.2012.07.001 - DOI - PubMed
-
- Biswas S, Reddy ND, Jayashree BS, Rao CM (2018) Evaluation of novel 3-hydroxyflavone analogues as HDAC inhibitors against colorectal cancer. Adv Pharmacol Sci 2018:1–14. https://doi.org/10.1155/2018/4751806 - DOI
-
- Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB (2021) Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol 87(12):4577–4597. https://doi.org/10.1111/bcp.14889 - DOI - PubMed
-
- Bora-Tatar G, Dayangaç-Erden D, Demir AS, Dalkara S, Yelekçi K, Erdem-Yurter H (2009) Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorg Med Chem 17(14):5219–5228. https://doi.org/10.1016/j.bmc.2009.05.042 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous